BG Medicine (BGMD) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
BG Medicine Reports Third Quarter 2014 Financial Results
November 13, 2014 6:30 AM ESTNet Loss Reduced by 35% and Operating Cash Burn Cut by 48% From Third Quarter 2013
Company Retains Investment Bank to Explore Strategic Alternatives
WALTHAM, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- BGMedicine, Inc. (Nasdaq: BGMD), the developer of the BGM Galectin-3®Test, today reported financial results for the third quarter... More
